FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1821983332> ?p ?o ?g. }

• W1821983332 endingPage "17636" @default.
• W1821983332 startingPage "17621" @default.
• W1821983332 abstract "// Céline Gérard 1 , Mélanie Mestdagt 1 , Ekaterine Tskitishvili 1 , Laudine Communal 2 , Anne Gompel 2,3 , Elisabete Silva 4 , Jean-François Arnal 5 , Françoise Lenfant 5 , Agnès Noel 1 , Jean-Michel Foidart 1 and Christel Péqueux 1 1 Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, Liège, Belgium 2 Gynaecological Endocrinology Unit, Paris Descartes University, Hôpitaux Universitaires, Paris, France 3 INSERM U 938, UPMC, Paris 4 Institute of Environment, Health and Societies, Brunel University London, UB83PH Uxbridge, United Kingdom 5 INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires, University of Toulouse, UPS, Toulouse, France Correspondence to: Christel Péqueux, email: // Keywords : estetrol, menopause, breast cancer, estrogen receptor, SERM Received : March 03, 2015 Accepted : May 02, 2015 Published : May 19, 2015 Abstract Increased risk of breast cancer is a critical side effect associated with the use of a menopausal hormone therapy (MHT). Estetrol (E4) is a natural estrogen produced by the human fetal liver and is a promising compound for clinical use in MHT. However, its impact on breast cancer is controversial and poorly defined. In this preclinical study, we show that E4 acts as a weak estrogen by stimulating the growth of hormone-dependent breast cancer only at concentrations exceeding menopausal therapeutic needs. E4 presents also an antitumor activity by decreasing the strong proliferative effect of estradiol (E2). While estrogen receptor alpha (ERα) is the predominant receptor mediating its effects, the dual weak-estrogenic/anti-estrogenic feature of E4 results from differential signaling pathways activation. Both nuclear and rapid extra-nuclear signaling pathway are necessary for a complete estrogenic effect of E4. However, the antitumor action of E4 is not due to a capacity to antagonize E2-induced nuclear activity. Altogether, our results highlight that E4 has a limited impact on breast cancer and may offer a safe therapeutic window for the treatment of menopausal symptoms." @default.
• W1821983332 created "2016-06-24" @default.
• W1821983332 creator A5036465405 @default.
• W1821983332 creator A5040538111 @default.
• W1821983332 creator A5043815002 @default.
• W1821983332 creator A5050750512 @default.
• W1821983332 creator A5051690225 @default.
• W1821983332 creator A5053392492 @default.
• W1821983332 creator A5062387212 @default.
• W1821983332 creator A5069935922 @default.
• W1821983332 creator A5078213723 @default.
• W1821983332 creator A5078974321 @default.
• W1821983332 creator A5084744120 @default.
• W1821983332 date "2015-05-19" @default.
• W1821983332 modified "2023-10-16" @default.
• W1821983332 title "Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms" @default.
• W1821983332 cites W1586125594 @default.
• W1821983332 cites W1593442063 @default.
• W1821983332 cites W1777016109 @default.
• W1821983332 cites W1964729966 @default.
• W1821983332 cites W1976088074 @default.
• W1821983332 cites W1977061516 @default.
• W1821983332 cites W1981467972 @default.
• W1821983332 cites W1982196094 @default.
• W1821983332 cites W1992934818 @default.
• W1821983332 cites W2000836832 @default.
• W1821983332 cites W2001315800 @default.
• W1821983332 cites W2013322816 @default.
• W1821983332 cites W2023405117 @default.
• W1821983332 cites W2024905084 @default.
• W1821983332 cites W2026425636 @default.
• W1821983332 cites W2029331212 @default.
• W1821983332 cites W2033587232 @default.
• W1821983332 cites W2034277976 @default.
• W1821983332 cites W2037614536 @default.
• W1821983332 cites W2038208040 @default.
• W1821983332 cites W2038302740 @default.
• W1821983332 cites W2049413564 @default.
• W1821983332 cites W2050884304 @default.
• W1821983332 cites W2051237733 @default.
• W1821983332 cites W2057734021 @default.
• W1821983332 cites W2060599869 @default.
• W1821983332 cites W2064391759 @default.
• W1821983332 cites W2069257811 @default.
• W1821983332 cites W2073090360 @default.
• W1821983332 cites W2075443461 @default.
• W1821983332 cites W2080831030 @default.
• W1821983332 cites W2081199042 @default.
• W1821983332 cites W2092687612 @default.
• W1821983332 cites W2096938125 @default.
• W1821983332 cites W2101467600 @default.
• W1821983332 cites W2102041104 @default.
• W1821983332 cites W2115217138 @default.
• W1821983332 cites W2119793417 @default.
• W1821983332 cites W2124375064 @default.
• W1821983332 cites W2134873494 @default.
• W1821983332 cites W2137711105 @default.
• W1821983332 cites W2158276728 @default.
• W1821983332 cites W2169726583 @default.
• W1821983332 cites W2294121629 @default.
• W1821983332 cites W2338159909 @default.
• W1821983332 cites W2515721699 @default.
• W1821983332 cites W4319053026 @default.
• W1821983332 doi "https://doi.org/10.18632/oncotarget.4184" @default.
• W1821983332 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4627333" @default.
• W1821983332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26056044" @default.
• W1821983332 hasPublicationYear "2015" @default.
• W1821983332 type Work @default.
• W1821983332 sameAs 1821983332 @default.
• W1821983332 citedByCount "32" @default.
• W1821983332 countsByYear W18219833322015 @default.
• W1821983332 countsByYear W18219833322016 @default.
• W1821983332 countsByYear W18219833322017 @default.
• W1821983332 countsByYear W18219833322018 @default.
• W1821983332 countsByYear W18219833322019 @default.
• W1821983332 countsByYear W18219833322020 @default.
• W1821983332 countsByYear W18219833322021 @default.
• W1821983332 countsByYear W18219833322022 @default.
• W1821983332 countsByYear W18219833322023 @default.
• W1821983332 crossrefType "journal-article" @default.
• W1821983332 hasAuthorship W1821983332A5036465405 @default.
• W1821983332 hasAuthorship W1821983332A5040538111 @default.
• W1821983332 hasAuthorship W1821983332A5043815002 @default.
• W1821983332 hasAuthorship W1821983332A5050750512 @default.
• W1821983332 hasAuthorship W1821983332A5051690225 @default.
• W1821983332 hasAuthorship W1821983332A5053392492 @default.
• W1821983332 hasAuthorship W1821983332A5062387212 @default.
• W1821983332 hasAuthorship W1821983332A5069935922 @default.
• W1821983332 hasAuthorship W1821983332A5078213723 @default.
• W1821983332 hasAuthorship W1821983332A5078974321 @default.
• W1821983332 hasAuthorship W1821983332A5084744120 @default.
• W1821983332 hasBestOaLocation W18219833322 @default.
• W1821983332 hasConcept C121608353 @default.
• W1821983332 hasConcept C126322002 @default.
• W1821983332 hasConcept C134018914 @default.
• W1821983332 hasConcept C143998085 @default.
• W1821983332 hasConcept C2777164284 @default.
• W1821983332 hasConcept C2777944059 @default.

• next